PVI
AVDL

Pura Vida Investments’s Avadel Pharmaceuticals AVDL Stock Holding History

Pura Vida Investments’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-260,000
Closed -$1.86M – 87
2022
Q4 		$1.86M Buy
260,000
+174,242
+203% +$1.22M 0.1% 127
2022
Q3 		$430K Sell
85,758
-703,423
-89% -$3.87M 0.02% 176
2022
Q2 		$1.93M Buy
+789,181
New +$3.24M 0.11% 143
2021
Q3 		– Sell
-176,206
Closed -$1.39M – 282
2021
Q2 		$1.19M Sell
176,206
-57,916
-25% -$460K 0.04% 173
2021
Q1 		$2.12M Sell
234,122
-155,449
-40% -$1.26M 0.06% 160
2020
Q4 		$2.6M Sell
389,571
-405,629
-51% -$2.54M 0.09% 132
2020
Q3 		$4.01M Buy
795,200
+232,400
+41% +$1.69M 0.21% 97
2020
Q2 		$4.55M Buy
562,800
+66,140
+13% +$583K 0.44% 60
2020
Q1 		$3.94M Buy
496,660
+387,660
+356% +$2.98M 0.47% 47
2019
Q4 		$823K Sell
109,000
-12,435
-10% -$65.7K 0.07% 93
2019
Q3 		$505K Buy
+121,435
New +$304K 0.09% 89

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Pura Vida Investments's AVDL Position: Q1 2023 in Review

Pura Vida Investments sold out of Avadel Pharmaceuticals (AVDL) in Q1 2023, closing a stake of 260,000 shares — an estimated $1.86M sold.

Pura Vida Investments first reported a position in AVDL in Q3 2019 and held it in 11 quarters. The position peaked at $4.55M in Q2 2020. 93 funds tracked by Wall St. Rank hold AVDL as of Q1 2023.

  • Pura Vida Investments reported no remaining Avadel Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 260,000 Avadel Pharmaceuticals shares in Q1 2023, an estimated $1.86M.
  • Pura Vida Investments first reported a position in Avadel Pharmaceuticals in Q3 2019 and held it in 11 quarters.
  • Pura Vida Investments's Avadel Pharmaceuticals position peaked at $4.55M in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.